临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 98717-15-8

Ropivacaine HCl

中文名称:盐酸罗哌卡因
CAS号:98717-15-8
分子式: C17H26N2O.HCl 分子量: 310.86
产品形式: HCl
研发状态: Not yet recruiting
研发用途: Pain Postoperative
研究机构: The University of Hong Kong
研发日期: March 1 2024
研发阶段: Phase 4
Ropivacaine HCl (LEA-103) is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly.

CAS: 98319-26-7

Finasteride

中文名称:非那雄胺
CAS号:98319-26-7
分子式: C23H36N2O2 分子量: 372.54
产品形式: free base
研发状态: Recruiting
研发用途: Benign Prostatic Hyperplasia; Prostate Hyperplasia; Prostate Disease; Prostate Hypertrophy; Prostate Pain; Lower Urinary Tract Symptoms; Urinary Obstruction; Urinary Tract Disease
研究机构: Beth Israel Deaconess Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
研发日期: September 25 2020
研发阶段: Not Applicable
Finasteride (MK-906) is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with Ki of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).

CAS: 979-32-8

Estradiol valerate

中文名称:戊酸雌二醇
CAS号:979-32-8
分子式: C23H32O3 分子量: 356.50
产品形式: free base
研发状态: Completed
研发用途: Oral Contraception
研究机构: Bayer
研发日期: June 24 2021
研发阶段: --
Estradiol(E2V) is a synthetic ester used to treat menopausal symptoms and hormone deficiencies.

CAS: 97-77-8

Disulfiram (NSC 190940)

中文名称:促进剂TETD
CAS号:97-77-8
分子式: C10H20N2S4 分子量: 296.54
产品形式: free base
研发状态: Recruiting
研发用途: Inherited Retinal Dystrophy Primarily Involving Sensory Retina
研究机构: University of Washington
研发日期: Dec-23
研发阶段: Phase 1 : Phase 2
Disulfiram (NSC 190940, Tetraethylthiuram disulfide, TETD) is a specific inhibitor of aldehyde-dehydrogenase (ALDH) with IC50 of 0.15 μM and 1.45 μM for hALDH1 and hALDH2, respectively. Disulfiram is used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram induces apoptosis. Disulfiram is also an inhibitor of pore formation by gasdermin D (GSDMD).

CAS: 97682-44-5

Irinotecan (CPT-11)

中文名称:伊立替康
CAS号:97682-44-5
分子式: C33H38N4O6 分子量: 586.68
产品形式: Free Base
研发状态: Recruiting
研发用途: Metastatic Colorectal Cancer
研究机构: University of Wisconsin Madison; Ipsen
研发日期: October 13 2023
研发阶段: Phase 2
Irinotecan (CPT-11, (+)-Irinotecan) is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

CAS: 976-71-6

Canrenone

中文名称:坎利酮
CAS号:976-71-6
分子式: C22H28O3 分子量: 340.46
产品形式: free base
研发状态: Not yet recruiting
研发用途: Edema Due to Heart Failure or Cirrhosis
研究机构: CMP Development LLC
研发日期: Jun-24
研发阶段: Phase 4
Canrenone (Aldadiene, SC-9376, RP-11614, 6,7-Dehydro-7α-desthioacetylspironolactone), a cardiovascular drug, a sort of steroid, is spironolactone's major metabolite and has been widely used as a nonselective aldosterone receptor antagonist clinically to treat heart failure, high blood pressure, edema, liver ascites, and other cardiovascular diseases.